| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.046 | 0.1 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.047 | 0.1 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.066 | 0.1 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.1 |